Our director, John Gerardi was in National Review this past weekend writing about the recent Supreme Court decision about mifepristone, the abortion pill.
Last week, the Supreme Court issued a ruling allowing the current, Biden-era rules for dispensing the abortion pill to remain in place while the state of Louisiana sues the FDA over the legality of those rules. Since 2021 (formalized in 2023), the FDA has allowed the abortion pill to be prescribed via telemedicine visits and shipped to patients directly through the mail. This has led to the total number of American abortions increasing from 900,000 per year at the start of the Biden Administration, to 1.1 million today, with the increase mainly driven by mifepristone abortions. 63% of American abortions are performed via mifepristone, and roughly 28% of abortions are performed with telemedicine and shipping through the mail.
This decision should be an inflection point for the Trump Administration, which has been defending these regulations in court. The Trump Administration’s promised safety review of mifepristone has been enormously delayed, and has not even started.
President Trump and his new acting FDA Commissioner, the pro-life Kyle Diamantas should stop opposing this lawsuit and enact swift measures to limit the flow of abortion drugs. You can read John’s full article at the link.